Rassegna stampa
Dermatologia27 mar 2017
Bambini in Italia troppo al sole, uno su quattro si scotta
Presentati al ministero dell’Istruzione i risultati della campagna educativa 'Il sole per amico' che ha coinvolto 50.000 alunni delle scuole primarie della penisola
20 mar 2017
FDA Approves Pembrolizumab for Certain Patients With Hodgkin Lymphoma
The US Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and paediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after 3 or more prior lines of therapy
20 mar 2017
Antibiotics Not Effective for Clinically Infected Eczema in Children
There is no meaningful benefit from the use of either oral or topical antibiotics for milder clinically infected eczema in children, according to a study published in the March/April issue of Annals of Family Medicine
20 mar 2017
Oral Agent Appears to Clear Fungal-Infected Nails
An investigative oral agent, VT-1161, appears to restore nails with moderate-to-severe fungus infection to their normal state, according to results of a phase 2b study presented here at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
20 mar 2017
Certolizumab Offers Relief From Moderate-to-Severe Psoriasis
Patients who received the targeted agent certolizumab for chronic moderate-to-severe plaque psoriasis achieved better outcomes than patients assigned to placebo -- even to the point of having nearly clear skin after 16 weeks of treatment, according to results from 2 similar phase 3 trials, reported at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
20 mar 2017
Serlopitant Benefits Patients With Prurigo Nodularis
The investigative agent serlopitant appears to offer some relief from the disfiguring and intensely itchy skin eruptions of prurigo nodularis, according to results of a phase 2 study presented at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
20 mar 2017
Long-Term Treatment With Dupilumab Plus Topical Corticosteroids Controls Atopic Dermatitis
Long-term follow-up with the investigative biologic agent dupilumab in the treatment of patients with moderate-to-severe atopic dermatitis demonstrated a significant advantage with treatment over placebo, researchers reported at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
20 mar 2017
Psoriasi, al via la campagna: Chiedi al tuo dermatologo
Una chiamata all'azione per tutti coloro che soffrono della malattia, a chiedere nuove risposte per la propria pelle
20 mar 2017
Melanoma, anche l'alcol tra i fattori di rischio?
L'alcol è un fattore di rischio conclamato per alcuni tipi di tumore, come quello al fegato, all'esofago e all'orofaringe. Ma la lista potrebbe allungarsi con l'inclusione del melanoma, la forma più grave di tumore cutaneo
14 mar 2017
Psoriasi, i nuovi obiettivi terapeutici che rivoluzioneranno le cure
Tre malati su 4 non fanno sesso a causa della patologia, ma ora saranno ritenuti validi solo trattamenti che raggiungono alti livelli di efficacia
14 mar 2017
Dermatite atopica. Un problema anche per l'adulto e con incidenza in aumento
Questa patologia colpisce oggi il 2-5% della popolazione. Nelle sue forme più gravi il costante prurito e le manifestazioni dei sintomi sulla pelle portano a ripercussioni psicologiche forti per i pazienti. Sanofi e Regeneron Pharmaceuticals, Inc hanno presentato un farmaco sperimentale che sembra garantire un risultato migliore rispetto alle terapie più classiche a base di cortisone.
14 mar 2017
Spray Replaces Lost Skin Bacteria, Improves Keratosis Pilaris
A treatment that replaces natural-biome bacteria with ammonia-oxidising bacteria appears to improve the cosmetic appearance and texture of keratosis pilaris, according to results of a small phase 2 study reported at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
14 mar 2017
Patients With Immunosuppressive Diseases/Treatments Experience Greater Complications After Mohs Surgery
The risk of a patient having a complication following Mohs Micrographic Surgery increases if that patient has a history of immunosuppressive diseases or treatments, according to results of a 4-year retrospective, chart review presented at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
14 mar 2017
Topical Oxymetazoline 1.0% Shows Long-Term Efficacy for Persistent Facial Erythema Associated With Rosacea
Patients were able to tolerate treatment of their rosacea with topical 1% oxymetazoline hydrochloride gel for 1 year with acceptable reduction of redness and few adverse events, according to a study presented here at the 75th Annual Meeting of the American Academy of Dermatology (AAD)
13 mar 2017
Ixekizumab Superior to Ustekinumab for Treating Psoriasis
Patients with psoriasis treated with the targeted agent ixekizumab appear to have better outcomes at 24 weeks than those treated with ustekinumab, according to the 24-week data of the ongoing IXORA-S trial presented at the 2017 Annual Meeting of the American Academy of Dermatology (AAD)
13 mar 2017
Patients Aged Older Than 85 Years Who Have Mohs Surgery Average 6 More Years of Life
Patients aged older than 85 years can safely undergo Mohs micrographic surgery to remove non-melanoma skin cancer and still have years of good quality of life, researchers reported here at the 75th Annual Meeting of the American Academy of Dermatology (AAD)
13 mar 2017
Psoriasi, la terapia non è sufficiente per un malato su cinque
Un quinto dei pazienti seguiti con la cosiddetta «terapia sistemica» continua ad avere problemi significativi. Non bastano solo i farmaci, serve anche la pratica di stili di vita corretti: fumo e sovrappeso peggiorano le lesioni
13 mar 2017
Psoriasi, con la depressione sale il rischio di sviluppare artrite psoriasica?
Psoriasi e depressione, un'accoppiata nota da tempo ma da tenere sotto controllo.
13 mar 2017
Psoriasi. Niente vita di coppia per il 75% dei pazienti
Il 90% dei soggetti con psoriasi genitale dichiara effetti negativi sull’umore, il 75% dice addio alla propria vita sessuale e il 55% riporta una riduzione del desiderio sessuale a causa della malattia. Questi i dati presentati all’annuale appuntamento all’American Academy of Dermatology di Orlando
13 mar 2017
Psoriasi. Presentati al meeting annuale dell'American Academy of Dermatology i risultati di ixekizumab
Arrivano dall'Annual Meeting dell'American Academy of Dermatology in corso a Orlando i dati sull'efficacia a lungo termine di ixekizumab di Eli Lilly per la cura della psoriasi in forma da moderata a grave.